Life of Quaid E Azam

Only available on StudyMode
  • Download(s) : 301
  • Published : March 29, 2013
Open Document
Text Preview
ACCF/AHA Pocket Guideline
Adapted from the 2011 ACCF/AHA

Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy November 2011
Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons

© 2011 by the American College of Cardiology Foundation and the American Heart Association, Inc.

The following material was adapted from the 2011 ACCF/AHA Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy (J Am Coll Cardiol 2011;XX:XX–XX). This pocket guideline is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource. org) and the American Heart Association (my.americanheart.org).

For copies of this document, please contact Elsevier Inc. Reprint Department, e-mail: reprints@elsevier.com; phone: 212-633-3813; fax: 212-633-3820.

Permissions: Multiple copies, modification, alteration, enhancement, and/ ordistribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier’s permission department at healthpermissions@elsevier.com.

Contents
1. Introduction .........................................................................................3

2. Clinical Definition ................................................................................6

3. Genetic Testing Strategies/Family Screening .....................................7

4. Genotype-Positive/Phenotype-Negative Patients .............................9

5. Echocardiography .............................................................................. 10

6. Stress Testing ..................................................................................... 14

7. Cardiac Magnetic Resonance ............................................................ 15

8. Detection of Concomitant Coronary Disease ................................... 17

9. Asymptomatic Patients ..................................................................... 19

10. Pharmacologic Management........................................................... 21

11. Invasive Therapies ........................................................................... 26

12. Pacing .............................................................................................. 29

13. Sudden Cardiac Death Risk Stratification ..................................... 30

14. Selection of Patients for Implantable Cardioverter-Defibrillators ...32

15. Participation in Competitive or Recreational Sports and Physical Activity ...................................................................... 36

16. Management of Atrial Fibrillation ................................................. 38

17. Pregnancy/Delivery ........................................................................ 41

2

1. Introduction

The impetus for the guidelines is based on an appreciation of the frequency of this clinical entity and a realization that many aspects of clinical management, including the use of diagnostic modalities, genetic testing, utilization of implantable cardioverter-defibrillators (ICDs), and therapies for refractory symptoms lack consensus. The discussion and recommendations about the various diagnostic modalities apply to patients with established HCM and to a variable extent to patients with a high index of suspicion of the disease. Classification of Recommendations The ACCF/AHA classifications of recommendations and levels of evidence are utilized, and described in more detail in Table 1.

3

Applying Classification of Recommendations and LevelRecommendations and Level of Evidence Table 1. Applying Classification of of Evidence

Table 1. Applying Classification of...
tracking img